Acoustic Pharyngometers and SNAP Testing System
Customize your policy alerts
Sign up for Aetna Policy 0336 alerts
Get alerted when Policy 0336 changes without checking for updates manually.
Monitor payer policy activity
Governs Aetna's coverage stance for acoustic pharyngometry devices and variants of the SNAP Testing System for evaluation of obstructive sleep apnea (OSA), specifying which device configurations are considered medically necessary versus experimental/investigational for adults.
No material clinical or coverage changes in this revision.
Coverage Criteria
Not Medically Necessary / Experimental
Covered when ALL of the following are met:
Aetna permits use of the SNAP Testing System only when the device records a minimum of 3 channels and the criteria in CPB 0004 - Obstructive Sleep Apnea in Adults are met; in that specific context SNAP (≥3 channels) is considered medically necessary for home diagnosis of OSA in adults. Documentation should support use of a type IV home sleep test (HCPCS G0400) with at least 3 channels when submitting for coverage.
Conversely, acoustic pharyngometry (for example, the Eccovision Acoustic Pharyngometer) and versions of the SNAP Testing System that record fewer than 3 channels are considered experimental and investigational for screening, diagnosis, treatment planning, prediction of surgical success in suspected or known OSA, and for all other indications because effectiveness has not been established and these configurations may be insufficient to support clinical decisions.
Acoustic pharyngometry measurements should not be treated as interchangeable with cone beam computed tomography (CBCT). A study comparing AP with CBCT found only a moderate correlation for area (r = 0.43) and volume (r = 0.59) and the authors concluded the two methods are not interchangeable; therefore AP should not be used to replace CBCT when CBCT is required for clinical decision-making.
Practitioners should recognize measurement limitations of AP and SNAP devices: many published studies are feasibility or nonrandomized designs, often performed by experienced operators under awake/upright conditions that may not reflect sleep physiology. These limitations reduce the ability of AP-derived measures to serve as sole diagnostic evidence for OSA.
Versions of the SNAP Testing System that use fewer than 3 channels and acoustic pharyngometry devices are explicitly designated not medically necessary / experimental and investigational for all OSA-related uses. The policy states there is insufficient evidence that home SNAP devices with <3 channels are as effective as conventional sleep studies for diagnosis and treatment planning, and thus these configurations may be denied.
FDA 510(k) clearance of a device does not by itself establish clinical effectiveness or interchangeability with gold-standard diagnostic tests; the policy therefore distinguishes device regulatory status from medical necessity and treats SNAP <3-channel versions and acoustic pharyngometry as investigational despite any 510(k) clearance.
Major diagnostic reviews do not support acoustic pharyngometry as a standalone diagnostic tool for obstructive sleep apnea. For example, an UpToDate review on clinical presentation and diagnosis of OSA does not mention acoustic pharyngometry, and the literature documents reproducibility and validity concerns for AP measures.
Because AP studies frequently involve awake, seated measurements, experienced operators, and nonrandomized or feasibility designs, Aetna does not support use of acoustic pharyngometry as the sole basis for diagnosing OSA or for making definitive treatment decisions; reliance on AP alone carries a risk of claim denial.
Coding
| G0400 | Home sleep test (HST) with type IV portable monitor, unattended; minimum of 3 channels [covered for adults only] |
| F51.03 - F51.05 | Insomnia and hypersomnia not due to a substance or known physiological condition |
| F51.13 - F51.19 | Insomnia and hypersomnia not due to a substance or known physiological condition |
| F51.8 | Other sleep disorders not due to a substance or known physiological condition |
| G47.00 - G47.39 | Sleep disorders |
| G47.50 - G47.9 | Sleep disorders |
| R06.00 - R06.09 | Abnormalities of breathing |
| R06.83 - R06.89 | Abnormalities of breathing |
| R06.81 | Apnea, not elsewhere classified |
| None specified | No specific CPT/HCPCS code listed for acoustic pharyngometry device |
| K011329 | Eccovision Acoustic Diagnostic Imaging Acoustic Pharyngometer (FDA 510(k) No. K011329) |
| K992322 | Snap Model 5. Apnea/snoring recording and analysis device and oximeter (FDA 510(k) No. K992322) |
Provider Actions and Documentation
Prior authorization required for HST (≥3 channels)
Home sleep test (HST) using a type IV portable monitor with a minimum of 3 channels (HCPCS G0400) is covered for adults when selection criteria in CPB 0004 are met; submit prior authorization referencing G0400 and the applicable CPB 0004 criteria.
- Use HCPCS code G0400 for prior auth submission.
- Ensure patient meets CPB 0004 selection criteria for OSA diagnosis.
Document device model and FDA 510(k) when requested
If device-level clearance is required by the payer, document the exact device model and the FDA 510(k) number (for example, Eccovision K011329 or SNAP Model 5 K992322) in the authorization and medical record.
- Provide manufacturer and model name.
- Include FDA 510(k) number in supporting documentation when requested.
Use established diagnostic steps first
Follow established diagnostic pathways (eg, polysomnography or type III/IV devices per CPB 0004) before relying on acoustic pharyngometry or single-/fewer‑channel SNAP systems to guide clinical decisions.
- Consider polysomnography or validated home sleep testing prior to using AP/SNAP for treatment planning.
- Do not substitute AP/SNAP (<3 channels) for standard diagnostic tests.
Consider established diagnostic steps first (clinical caution)
Recognize that studies of acoustic pharyngometry often used experienced operators and non-randomized designs; consider validated diagnostic methods (eg, polysomnography, type III devices) prior to using AP to direct therapy.
- AP measures may lack reproducibility and validity outside experienced operators.
- Prefer standard diagnostic tests for treatment decisions.
Document device type, channel count, and selection criteria for HST
When submitting claims for HCPCS G0400, include documentation that the test used a type IV portable monitor with at least 3 channels and that patient selection criteria in CPB 0004 were met; retain the HST report in the medical record.
- Document device type (type IV) and channel count (≥3) in the chart and claim support.
- Keep the HST report and interpretation available for review.
Document diagnostic device and scoring in protocols/studies
If acoustic pharyngometry or SNAP is used within a study or clinical protocol, record the device type, scoring method, and baseline/follow‑up sleep study methodology (including whether manual scoring was used) to support interpretation of results.
- Specify device and scoring method in study records.
- Document baseline and follow‑up sleep study devices and whether manual scoring was performed.
Denial risk: AP and SNAP versions with <3 channels
Use of acoustic pharyngometry or SNAP systems with fewer than 3 channels for screening, diagnosis, treatment planning, or prediction of surgical success is considered experimental/investigational and may be denied.
- Do not rely on AP or SNAP <3 channels for clinical decisions expecting coverage.
- Expect denials for claims using these devices for OSA‑related indications.
Denial risk if AP used as sole diagnostic evidence
Acoustic pharyngometry has reproducibility and validity limitations and is not referenced in major diagnostic reviews (eg, UpToDate); using AP as the sole diagnostic evidence for OSA may be insufficient to support coverage and could be denied.
- Avoid using AP alone to establish OSA diagnosis for coverage purposes.
- Provide corroborating sleep study data when AP findings are used.
Definitions
Background
Acoustic pharyngometry noninvasively derives an area–distance curve of the upper airway by emitting and recording reflected sound waves to estimate cross‑sectional area and pharyngeal volume. It has been investigated for screening for OSA, assisting oral appliance positioning, and documenting anatomic changes after surgery, but studies vary in design and quality. Correlations with OSA severity and with imaging (eg, CBCT) have been reported, yet reproducibility and clinical interchangeability with gold‑standard methods remain limited.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.